RxSight Inc (RXST) concluded trading on Wednesday at a closing price of $7.95, with 16.7 million shares of worth about $132.8 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -77.82% during that period and on July 09, 2025 the price saw a loss of about -37.84%. Currently the company’s common shares owned by public are about 40.59M shares, out of which, 37.76M shares are available for trading.
Stock saw a price change of -39.41% in past 5 days and over the past one month there was a price change of -47.14%. Year-to-date (YTD), RXST shares are showing a performance of -86.04% which decreased to -76.88% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $12.38 but also hit the highest price of $58.23 during that period. The average intraday trading volume for RxSight Inc shares is 961.19K. The stock is currently trading -40.21% below its 20-day simple moving average (SMA20), while that difference is down -44.39% for SMA50 and it goes to -73.83% lower than SMA200.
RxSight Inc (NASDAQ: RXST) currently have 40.59M outstanding shares and institutions hold larger chunk of about 92.02% of that.
The stock has a current market capitalization of $323.06M and its 3Y-monthly beta is at 1.21. It has posted earnings per share of -$0.67 in the same period. It has Quick Ratio of 11.65 while making debt-to-equity ratio of 0.04. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for RXST, volatility over the week remained 10.22% while standing at 6.37% over the month.
Stock’s fiscal year EPS is expected to drop by -43.31% while it is estimated to increase by 9.06% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Wells Fargo on July 09, 2025 offering an Equal weight rating for the stock and assigned a target price of $9 to it. On July 09, 2025, BTIG Research Downgrade their recommendations, while on May 19, 2025, Wells Fargo Upgrade their ratings for the stock with a price target of $25. Stock get a Neutral rating from Piper Sandler on April 15, 2025.
